Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community ca

@article{Witzig2017LongtermFO,
  title={Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community ca},
  author={Thomas E Witzig and Patrick Gerard Johnston and Betsy R Laplant and Paul James Kurtin and Levi D Pederson and Dennis Moore and Nassim H Nabbout and Daniel A. Nikcevich and Kendrith M. Rowland and Axel M Grothey},
  journal={American journal of hematology},
  year={2017},
  volume={92 10},
  pages={1004-1010}
}
Patients with relapsed aggressive non-Hodgkin lymphoma (NHL) are often treated with platinum-based chemoimmunotherapy regimens in preparation for autologous stem cell transplant. We sought to reduce toxicity and maintain efficacy by using oxaliplatin with rituximab, cytarabine and dexamethasone (ROAD) in a phase II clinical trial in patients who had relapsed after one prior regimen. ROAD was delivered q21 days and consisted of rituximab 375 mg/m2 IV weekly x 4 doses (cycle 1 only… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS